Wynter C V, Simms L A, Buttenshaw R L, Biden K G, Young J, Leggett B A, Conrad R J, Schoch E M, Jass J R, Praga Pillay S
Department of Surgery, Greenslopes Private Hospital, University of Queensland, Brisbane, Australia.
J Pathol. 1999 Nov;189(3):319-25. doi: 10.1002/(SICI)1096-9896(199911)189:3<319::AID-PATH436>3.0.CO;2-2.
Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are two important determinants of angiogenesis in human cancers. Expression of VEGF and bFGF was examined by immunohistochemistry in 120 colorectal cancers. Neoplasms were classified according to the presence or absence of microsatellite instability determined at six microsatellite loci and labelled as a high microsatellite instability (MSI-H), low microsatellite instability (MSI-L) or microsatellite stable (MSS). Only 4/30 MSI-H cancers expressed VEGF (13 per cent), compared with 24/64 MSS cancers (38 per cent; p< 0.01). Fewer MSI-H cancers showed bFGF expression (38 per cent) than MSS cancers (53 per cent; p< 0.09). MSI-L cancers showed the same pattern as MSS cancers. Western blotting and immunohistochemistry showed that the tumour suppressor gene p53 was mutated infrequently in MSI-H cancers (8 per cent; p< 0. 001). Microvessel density counts using CD31 and UEA-1 demonstrated no difference in the number of blood vessels in MSI-H and MSS cancers. Although these results are consistent with the known role of wild-type p53 in down-regulating VEGF, no association was found between a mutation in p53 and VEGF or bFGF levels in all colonic neoplasms. This is the first evidence that MSI-H cancers may follow a different pathway to angiogenesis. The low frequency of VEGF expression amongst MSI-H cancers may partially explain why these cancers are less aggressive, with a better overall prognosis.
血管内皮生长因子(VEGF)和碱性成纤维细胞生长因子(bFGF)是人类癌症血管生成的两个重要决定因素。通过免疫组织化学检测了120例结直肠癌中VEGF和bFGF的表达。根据在六个微卫星位点确定的微卫星不稳定性的有无对肿瘤进行分类,并标记为高微卫星不稳定性(MSI-H)、低微卫星不稳定性(MSI-L)或微卫星稳定(MSS)。在30例MSI-H癌症中,只有4例表达VEGF(13%),相比之下,64例MSS癌症中有24例表达VEGF(38%;p<0.01)。与MSS癌症(53%;p<0.09)相比,MSI-H癌症中显示bFGF表达的较少(38%)。MSI-L癌症表现出与MSS癌症相同的模式。蛋白质印迹法和免疫组织化学显示,肿瘤抑制基因p53在MSI-H癌症中很少发生突变(8%;p<0.001)。使用CD31和UEA-1进行的微血管密度计数显示,MSI-H和MSS癌症中的血管数量没有差异。尽管这些结果与野生型p53在下调VEGF中的已知作用一致,但在所有结肠肿瘤中,未发现p53突变与VEGF或bFGF水平之间存在关联。这是MSI-H癌症可能遵循不同血管生成途径的首个证据。MSI-H癌症中VEGF表达频率低可能部分解释了为什么这些癌症侵袭性较小,总体预后较好。